How should a 32‑year‑old G2P1L1 woman at 33 weeks gestation presenting with fever, mild hemoptysis, significant weight loss, jaundice, pruritus, positive urine bile salts, elevated alkaline phosphatase, normal gamma‑glutamyl transferase, normal other liver enzymes, elevated bile acids, high erythrocyte sedimentation rate, pallor, and a past history of pulmonary tuberculosis be managed?

Urgent Dual Diagnosis: Active Tuberculosis with Intrahepatic Cholestasis of Pregnancy

This patient requires immediate hospitalization for concurrent management of active pulmonary tuberculosis (reactivation) and intrahepatic cholestasis of pregnancy (ICP), with urgent infectious disease and maternal-fetal medicine consultation to address both life-threatening conditions simultaneously.

Critical Clinical Assessment

This presentation represents two overlapping serious conditions requiring immediate action:

Active Tuberculosis Indicators

• Fever with hemoptysis in a patient with prior PTB history
• Significant weight loss over months
• ESR 120 (markedly elevated, consistent with active TB)
• Pallor suggesting chronic disease/anemia

Intrahepatic Cholestasis of Pregnancy

• Bile acids 39 μmol/L (elevated; normal <10 μmol/L)
• Pruritus with positive urine bile salts
• Direct hyperbilirubinemia (bilirubin 5 mg/dL, predominantly direct)
• Elevated alkaline phosphatase 316 with normal GGT (pregnancy-specific pattern)
• Normal transaminases (typical for ICP)

Immediate Management Algorithm

Step 1: Hospitalize and Stabilize (Day 1)

Tuberculosis workup:

• Chest X-ray with abdominal shielding (benefits outweigh minimal fetal radiation risk)
• Sputum for acid-fast bacilli smear and GeneXpert MTB/RIF
• HIV testing
• Complete blood count (assess anemia severity)

Obstetric assessment:

• Confirm gestational age with ultrasound
• Initiate antenatal fetal surveillance immediately (non-stress testing) 1
• Repeat bile acids weekly (can rise rapidly with advancing gestation) 2

Step 2: Initiate Treatment (Within 24-48 Hours)

For Tuberculosis: Start anti-TB therapy immediately given high clinical suspicion—do not wait for culture confirmation when hemoptysis and systemic symptoms are present. The standard regimen requires modification:

• Isoniazid 300 mg daily (safe in pregnancy)
• Rifampicin 600 mg daily (safe in pregnancy; may worsen cholestasis but benefits outweigh risks)
• Ethambutol 15-20 mg/kg daily (safe in pregnancy)
• Pyrazinamide 25 mg/kg daily (WHO recommends; avoid if severe hepatic dysfunction)
• Pyridoxine 25-50 mg daily (prevent isoniazid-induced neuropathy)

Critical caveat: Given the cholestasis and elevated bilirubin, monitor liver function tests every 10 days initially 3. If transaminases rise >3x upper limit of normal or bilirubin worsens significantly, consider holding pyrazinamide and extending treatment duration to 9 months.

For Intrahepatic Cholestasis:

• Ursodeoxycholic acid (UDCA) 15 mg/kg/day in divided doses (typically 900-1200 mg/day) 1, 2
• UDCA is GRADE 1A recommendation for symptom relief and may protect against stillbirth 1
• Continue until delivery, then taper over 2-4 weeks postpartum 2

Step 3: Delivery Timing Decision

With bile acids 39 μmol/L (<100 μmol/L):

• Plan delivery between 36-39 weeks gestation 1
• Given she is currently 33+3 weeks, continue weekly bile acid monitoring
• If bile acids rise >100 μmol/L, deliver at 36 weeks due to markedly increased stillbirth risk 1, 2
• Administer betamethasone for fetal lung maturity now (before 34 weeks) given high likelihood of preterm delivery 1

TB considerations for delivery:

• Patient will likely still be on treatment at delivery
• Ensure respiratory isolation precautions during labor/delivery if sputum still positive
• Vaginal delivery preferred unless obstetric indications for cesarean
• Breastfeeding is safe on anti-TB medications

Step 4: Monitoring Protocol Until Delivery

Weekly assessments:

• Non-stress testing or biophysical profile 1
• Serum bile acids (can escalate rapidly) 2
• Liver function tests (AST, ALT, bilirubin) every 10 days initially, then every 2 weeks if stable 3

TB monitoring:

• Sputum conversion status at 2 months
• Clinical response (fever resolution, weight stabilization)
• Adherence to directly observed therapy if possible

Critical Pitfalls to Avoid

1. Do not delay anti-TB treatment waiting for definitive diagnosis—hemoptysis with prior TB history and systemic symptoms warrants empiric treatment
2. Do not attribute all symptoms to ICP alone—the fever, hemoptysis, and weight loss are NOT explained by cholestasis
3. Do not use streptomycin (ototoxic to fetus) or fluoroquinolones as first-line agents in pregnancy
4. Do not delay delivery beyond 39 weeks even if bile acids remain <100 μmol/L 1
5. Do not stop UDCA abruptly at delivery—taper over 2-4 weeks if symptoms persist 2

Differential Considerations Ruled Out

The normal GGT with elevated alkaline phosphatase effectively rules out primary biliary cholangitis or primary sclerosing cholangitis 2. The pattern is classic for ICP where alkaline phosphatase is placental in origin. However, the marked systemic symptoms (fever, hemoptysis, weight loss, ESR 120) cannot be explained by ICP alone and point definitively to active tuberculosis.

Miliary TB can cause acute liver failure 4, but this patient's transaminases are normal, making hepatic TB less likely than pulmonary TB with concurrent ICP.

Postpartum Follow-up

• Confirm resolution of cholestasis (bile acids, LFTs) within 3 months postpartum 2
• Continue anti-TB therapy for full course (6-9 months total depending on pyrazinamide use)
• Counsel regarding 50% recurrence risk of ICP in future pregnancies 2
• Breastfeeding is safe and encouraged on both UDCA and anti-TB medications